These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30467061)

  • 21. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge.
    Zhang Y; Masi AW; Barniak V; Mountzouros K; Hostetter MK; Green BA
    Infect Immun; 2001 Jun; 69(6):3827-36. PubMed ID: 11349048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance of young mice to pneumococcal infection can be improved by oral vaccination with recombinant Lactococcus lactis.
    Villena J; Medina M; Racedo S; Alvarez S
    J Microbiol Immunol Infect; 2010 Feb; 43(1):1-10. PubMed ID: 20434117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice.
    Wu K; Zhang X; Shi J; Li N; Li D; Luo M; Cao J; Yin N; Wang H; Xu W; He Y; Yin Y
    Infect Immun; 2010 Mar; 78(3):1276-83. PubMed ID: 20038538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterologous prime-boost immunization with live SPY1 and DnaJ protein of Streptococcus pneumoniae induces strong Th1 and Th17 cellular immune responses in mice.
    Qiu Y; Zhang X; Wang H; Zhang X; Mo Y; Sun X; Wang J; Yin Y; Xu W
    J Microbiol; 2017 Oct; 55(10):823-829. PubMed ID: 28956354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA).
    Katsurahara T; Hotomi M; Yamauchi K; Billal DS; Yamanaka N
    J Infect Chemother; 2008 Dec; 14(6):393-8. PubMed ID: 19089550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains.
    Yu J; Chen X; Li B; Gu T; Meng X; Kong W; Wu Y
    Immunol Res; 2018 Aug; 66(4):528-536. PubMed ID: 30128745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?
    Avila-Aguero ML; Ulloa-Gutierrez R; Falleiros-Arlant LH; Porras O
    Expert Rev Vaccines; 2017 Jul; 16(7):1-4. PubMed ID: 28535704
    [No Abstract]   [Full Text] [Related]  

  • 31. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of regulated delayed attenuation strategies for Salmonella enterica serovar Typhi vaccine vectors in neonatal and infant mice.
    Shi H; Wang S; Curtiss R
    Clin Vaccine Immunol; 2013 Jun; 20(6):931-44. PubMed ID: 23616408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced protective responses to a serotype-independent pneumococcal vaccine when combined with an inactivated influenza vaccine.
    Babb R; Chen A; Ogunniyi AD; Hirst TR; Kara EE; McColl SR; Alsharifi M; Paton JC
    Clin Sci (Lond); 2017 Jan; 131(2):169-180. PubMed ID: 27885052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins.
    Basset A; Thompson CM; Hollingshead SK; Briles DE; Ades EW; Lipsitch M; Malley R
    Infect Immun; 2007 Nov; 75(11):5460-4. PubMed ID: 17698570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
    Xu Q; Pryharski K; Pichichero ME
    Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae.
    Xu JH; Dai WJ; Chen B; Fan XY
    Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage.
    Ojal J; Hammitt LL; Gaitho J; Scott JAG; Goldblatt D
    Vaccine; 2017 Aug; 35(35 Pt B):4652-4657. PubMed ID: 28739116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.
    Pimenta FC; Miyaji EN; Arêas AP; Oliveira ML; de Andrade AL; Ho PL; Hollingshead SK; Leite LC
    Infect Immun; 2006 Aug; 74(8):4939-44. PubMed ID: 16861686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.
    Tian H; Groner A; Boes M; Pirofski LA
    Infect Immun; 2007 Apr; 75(4):1643-50. PubMed ID: 17220309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.